ライフサイエンスコーパス: corneal transplant

1 stantial mismatch between need and supply of corneal transplant.

2 atients who had undergone a unilateral first corneal transplant.

3 een accidentally transmitted by contaminated corneal transplants.

4 asing success in patients who have undergone corneal transplants.

5 ved in generating the alloimmune response to corneal transplants.

6 osis in the failure of orthotopic allogeneic corneal transplants.

7 layed-type hypersensitivity and rejection of corneal transplants.

8 le hope of visual recovery from conventional corneal transplants.

9 or histocompatibility complex MHC-mismatched corneal transplants.

10 measures were follow-up inquiries from 6592 corneal transplants.

11 hown to participate in long-term survival of corneal transplants.

12 The indication for corneal transplant affects the risk for developing postk

13 e over time during the study period for both corneal transplant and cataract surgery procedures; howe

14 Such a test might enhance safety of corneal transplants and some other tissue-derived produc

15 thways can significantly promote survival of corneal transplants, and suggest that select deletion or

16 As corneal transplants are met with high rejection rates in

17 ining lymph nodes of allogeneic or syngeneic corneal transplanted BALB/c mice.

18 ation when they were recipients of syngeneic corneal transplants but also exhibited significantly inc

19 a major barrier to the success of allogeneic corneal transplants, but the specific mediators and mech

20 mpared with the cataract surgery cohort, the corneal transplant cohort had a higher adjusted hazard r

21 ence rates ranged from 0.11% to 1.05% in the corneal transplant cohort, 0.06% to 0.20% in the catarac

22 e was a wider year-to-year variation for the corneal transplant cohort.

23 More corneal transplants, especially DALKs and endokeratoplas

24 nex and enzyme-linked immunosorbent assay on corneal transplant extracts at different times after sur

25 rgeons enrolled 1090 participants undergoing corneal transplant for a moderate-risk condition, princi

26 ents were included who had undergone a first corneal transplant for keratoconus (KC), Fuchs endotheli

27 CB6F1 mice were grafted with orthotopic corneal transplants from C3H donors (mismatch at the ent

28 atibility, including H-Y incompatibility, on corneal transplant graft rejection and failure.

29 Patients with corneal transplants have a high frequency of developing

30 rategies including NSAIDs, steroids, MMC and corneal transplants have shown tremendous success but wi

31 Allogeneic T cells from corneal transplant hosts promote VEC proliferation, prob

32 APC-dependent direct response is elicited in corneal transplant hosts when the graft bed is inflamed

33 f CCR1 can be a useful therapeutic target in corneal transplant immunity.

34 phy (FECD) is the most common indication for corneal transplant in the United States.

35 defense mechanism and may enable subsequent corneal transplant in these patients.

36 All corneal transplants in both the control and the topical

37 Second and subsequent corneal transplants in the same eye are more prone to re

38 In corneal-transplanted mice, the CD4+ T-cell response was

39 he trend of infectious endophthalmitis after corneal transplant or cataract surgery through examining

40 Patients undergoing corneal transplant or cataract surgery were identified u

41 lmitis at 6-week and 6-month intervals after corneal transplant or cataract surgery.

42 of center or surgeon transplant workload on corneal transplant outcome.

43 .5), or a previous history of multiple donor corneal transplants (P > .5).

44 The United States, with 199.10-6 corneal transplants per capita, had the highest transpla

45 if registering more than 50 and less than 10 corneal transplants per year, respectively; surgeons wer

46 In 2012, we identified 184,576 corneal transplants performed in 116 countries.

47 Almost half the corneal transplants performed in the United States are d

48 indications were Fuchs dystrophy (39% of all corneal transplants performed), a primary corneal edema

49 VEGF-C as a potentially important target in corneal transplant pharmacotherapy and immunobiology.

50 s than either normal controls (P = 0.017) or corneal transplant recipients not undergoing graft rejec

51 imulatory pathway promotes the acceptance of corneal transplants, regardless of the degree of allodis

52 om our prospective cohort from the Singapore Corneal Transplant Registry.

53 ic to EMAP between patients at high risk for corneal transplant rejection and control subjects (P<0.0

54 The rates of corneal transplant rejection were similar among B-cell-d

55 upports allograft survival in vivo, prevents corneal transplant rejection, and attenuates the progres

56 cal lymphangiogenesis mediates diseases like corneal transplant rejection, dry eye disease, and aller

57 of Fas mRNA expression in blood during human corneal transplant rejection.

58 vels of Fas mRNA in blood may have a role in corneal transplant rejection.

59 s and below were included from the Singapore Corneal Transplant Study between April 4, 1991 and April

60 om our prospective cohort from the Singapore Corneal Transplant Study.

61 ngoing prospective cohort from the Singapore Corneal Transplant Study.

62 d from subjects in the prospective Singapore Corneal Transplant Study.

63 om our prospective cohort from the Singapore Corneal Transplant Study.

64 , Germany, tertiary hospital, performing 500 corneal transplant surgeries per year.

65 The reasons for having combined glaucoma and corneal transplant surgery are myriad.

66 on of sVEGFR-3 leads to a 5-fold increase in corneal transplant survival in mouse models.

67 L-1 receptor antagonist (IL-1ra) can prolong corneal transplant survival in the murine model of ortho

68 Newer corneal transplant techniques may have a lower risk for

69 Recent advances in corneal transplant technology promise to repair the corn

70 4+ T cells and CD8+ T cells were examined in corneal transplants that expressed genetically defined m

71 survival of both minor H- and MHC-disparate corneal transplants to 100% (P = 0.0001) and 92% (P = 0.

72 antigen-mismatched (BALB.b; n=62) orthotopic corneal transplants to determine the effect of selective

73 Next, we investigated whether failure of corneal transplants to induce a CD4+ direct alloresponse

74 For corneal transplants undertaken in the periods 1999-2002,

75 Corneal transplants were done in BALB/c mice from C57BL/

76 A total of 3486 corneal transplants were undertaken: 1973 for FED, 1513

77 mune privileged site is the success of human corneal transplants, where a very high percentage of tra

78 ion and corneal graft rejection in high-risk corneal transplants with antecedent rejection or neovasc

79 bling clinicians and researchers to generate corneal transplants with sufficiently high fractions of